Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IMPAKT Breast Cancer Conference 2013 /
Long-term effectiveness of SERMs for preventing breast cancer

2nd - 4th May 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.05.13
Views: 4801
Rating:

Prof Jack Cuzick - Wolfson Institute of Preventive Medicine, London, UK

World-leading epidemiologist Prof Jack Cuzick talks to ecancer about his paper in the Lancet confirming that selective estrogen receptor modulators (SERMs) are both effective and safe for preventing breast cancer in women who are at high risk of the disease but who are not ill.

There has been caution about using tamoxifen and raloxifene (both SERMs) following scare stories in the US: Prof Cuzick's meta analysis addreses this and brings hope of avoiding a third of breast cancers.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation